Eton Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Eton Pharmaceuticals has been growing earnings at an average annual rate of 35.9%, while the Pharmaceuticals industry saw earnings growing at 12.2% annually. Revenues have been growing at an average rate of 38.6% per year. Eton Pharmaceuticals's return on equity is 27.2%, and it has net margins of 12%.
Key information
35.88%
Earnings growth rate
37.01%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.95% |
| Revenue growth rate | 38.55% |
| Return on equity | 27.24% |
| Net Margin | 12.02% |
| Last Earnings Update | 30 Jun 2026 |
Recent past performance updates
Recent updates
Analysis Article • Aug 19
Forecast: Analysts Think Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Business Prospects Have Improved Drastically
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Aug 14
Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These
Summary Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year revenue guidance raised to over $145 million. ETON targets over $500 million in peak annual sales by leveraging organic growth, pipeline development, and strategic acquisitions in rare disease markets. Management expects adjusted EBITDA margins to exceed 35% in 2026, aiming for 50% by 2028, with gross margins rising from 70% to over 75%. I rate ETON stock a Buy, supported by robust execution, scalable commercial strategy, and a 2-3 year target valuation above $2.5 billion despite current premium multiples. Read the full article on Seeking Alpha
Narrative Update • Aug 12
ETON: Ultra Rare Focus And New Guidance Will Drive Future Upside
Analysts have raised the fair value estimate for Eton Pharmaceuticals from $40 to $60. This change reflects updated models that factor in higher long term revenue assumptions for key products and recent price target increases across several research firms.
Narrative Update • Jul 28
ETON: Ultra Rare Disease Focus Will Drive Long Term Upside Potential
Analysts lifted the fair value estimate for Eton Pharmaceuticals to $62 from $57, reflecting updated price targets in the $60 to $62 range that factor in new product contributions, higher long term revenue assumptions for existing therapies, and more constructive views on its ultra rare disease portfolio. Analyst Commentary Recent Street research on Eton Pharmaceuticals points to a more constructive tone around the stock, with bullish analysts lifting price targets into the US$60 to US$62 range.Narrative Update • Jul 13
ETON: New Guidance And Drug Agreement Will Shape A Balanced Outlook
The analyst price target for Eton Pharmaceuticals has been raised from $52 to $57, with analysts citing updated fiscal 2026 revenue guidance and confidence in the company's growth strategy as key reasons for the change. What’s in the News for Eton Pharmaceuticals Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals, sold about 126,685 shares for roughly US$4.77 million between July 2 and July 7, 2026, at weighted average prices near US$37 to US$38 per share, while retaining around 2.7 million shares (source: recent SEC filings summarized in news reports).
Narrative Update • Jun 29
ETON: Orphan Therapy Portfolio Expansion Will Reshape Earnings Profile Through 2026
Eton Pharmaceuticals' analyst price targets have moved higher, with fair value estimates rising from about $39.33 to $45.67, as analysts point to updated revenue guidance and increased confidence in the company’s longer term growth plans. What’s in the News for Eton Pharmaceuticals Eton Pharmaceuticals was added to the S&P Pharmaceuticals Select Industry Index, reflecting its inclusion in a broader sector benchmark.Narrative Update • Jun 15
ETON: Higher 2026 Revenue Outlook Will Support Long Term Upside Potential
Analysts have raised their price target on Eton Pharmaceuticals to $57 from $52, citing the company's updated fiscal 2026 revenue guidance and their view that its long term growth goals remain achievable. Analyst Commentary Bullish analysts are pointing to Eton Pharmaceuticals' updated fiscal 2026 revenue guidance as a key support for their higher valuation frameworks.Narrative Update • Jun 01
ETON: Higher 2026 Guidance And New Rare Disease Assets Will Drive Upside
Analysts have lifted their fair value estimate for Eton Pharmaceuticals to $57 from $35, citing higher fiscal 2026 revenue guidance, stronger profitability assumptions, and confidence in the company’s growth strategy as key reasons for the revised valuation. Analyst Commentary Recent research updates show a clear cluster of bullish analysts raising their fair value assumptions on Eton Pharmaceuticals, with several target bumps tied directly to the company’s latest revenue outlook and portfolio moves.Narrative Update • May 03
ETON: Single New Acquisition Will Reshape Earnings Profile Through 2026 And Beyond
Analysts have lifted their price targets on Eton Pharmaceuticals by up to $15, citing updated assumptions for revenue growth, profit margins, and future P/E that reflect the recent Hemangeol acquisition and its potential contribution to the business. Analyst Commentary Recent research updates around Eton Pharmaceuticals focus heavily on the Hemangeol acquisition and how it might reshape the company’s growth mix, earnings profile, and valuation assumptions.Narrative Update • Apr 18
ETON: Hemangioma Acquisition Will Reshape Earnings Profile Through 2026 And Beyond
Narrative Update on Eton Pharmaceuticals Analysts have raised their price targets on Eton Pharmaceuticals by up to $15, citing the Hemangeol acquisition, its existing FDA approval for infantile hemangioma, and the view that the deal could be accretive with commercialization planned to begin in May. Analyst Commentary Bullish analysts are generally positive on Eton Pharmaceuticals following the acquisition of the U.S. rights to Hemangeol, and several have raised their price targets in response.Narrative Update • Apr 04
ETON: Hemangioma Franchise Expansion Will Reshape Earnings Profile Through 2026
Analysts have raised the consolidated price target for Eton Pharmaceuticals from $30.00 to about $39.33, citing recent target increases from multiple firms and updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research around Eton Pharmaceuticals focuses heavily on the updated price targets, the Hemangeol acquisition, and how realistic current modeling assumptions appear against execution risks.Narrative Update • Mar 21
ETON: Upcoming Product Launches And New Guidance Will Reshape Earnings Profile
Analysts have raised the Eton Pharmaceuticals price target from $26 to $31, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that reflect their latest views on the company following recent research updates. Analyst Commentary Recent research updates highlight a mix of optimism about Eton Pharmaceuticals' growth opportunities and caution around how quickly those opportunities might translate into earnings and justify higher valuation multiples.Analysis Article • Nov 14
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Share Price Matching Investor Opinion
With a price-to-sales (or "P/S") ratio of 6.4x Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) may be sending very bearish...Analysis Article • Sep 24
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Jun 17
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 25% Cheaper Price Remains In Tune With Revenues
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a horrible month, losing 25% after a relatively good period...New Narrative • May 16
Increlex And Galzin Acquisitions Will Broaden Treatment Options
Strategic acquisitions and product launches are expected to drive significant revenue growth and expand market reach in pediatrics and rare diseases.Analysis Article • May 16
Results: Eton Pharmaceuticals, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
It's been a pretty great week for Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders, with its shares surging 14...Analysis Article • May 02
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 33%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders are no doubt pleased to see that the share price has bounced...Analysis Article • Feb 07
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 45% Jump Shows Its Popularity With Investors
Despite an already strong run, Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have been powering on, with a gain of...Analysis Article • Nov 14
Investors Appear Satisfied With Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Prospects As Shares Rocket 29%
Despite an already strong run, Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have been powering on, with a gain of...Analysis Article • Oct 07
Is Eton Pharmaceuticals (NASDAQ:ETON) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysis Article • Sep 10
After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar
The Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) share price has done very well over the last month, posting an excellent...Analysis Article • Jan 09
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a really impressive month, gaining 40% after a shaky period...Analysis Article • Dec 13
The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot
Market forces rained on the parade of Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders today, when the covering...Analysis Article • Nov 16
Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point
Eton Pharmaceuticals, Inc.'s ( NASDAQ:ETON ) earnings announcement last week was disappointing for investors, despite...Analysis Article • Sep 30
Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Jul 25
Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%
Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shares have had a horrible month, losing 26% after a relatively good period...Analysis Article • Jun 29
Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Eton Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 26 | 106 | 13 | 38 | 6 |
| 31 Mar 26 | 87 | -1 | 37 | 8 |
| 31 Dec 25 | 80 | -5 | 35 | 8 |
| 30 Sep 25 | 70 | -7 | 33 | 5 |
| 30 Jun 25 | 58 | -4 | 30 | 5 |
| 31 Mar 25 | 48 | -5 | 26 | 4 |
| 31 Dec 24 | 39 | -4 | 22 | 3 |
| 30 Sep 24 | 35 | -5 | 21 | 5 |
| 30 Jun 24 | 31 | -7 | 20 | 5 |
| 31 Mar 24 | 34 | 1 | 19 | 3 |
| 31 Dec 23 | 32 | -1 | 19 | 3 |
| 30 Sep 23 | 33 | 2 | 19 | 3 |
| 30 Jun 23 | 29 | 0 | 19 | 3 |
| 31 Mar 23 | 24 | -6 | 19 | 3 |
| 31 Dec 22 | 21 | -9 | 19 | 4 |
| 30 Sep 22 | 19 | -9 | 18 | 4 |
| 30 Jun 22 | 16 | -12 | 17 | 6 |
| 31 Mar 22 | 12 | -12 | 15 | 7 |
| 31 Dec 21 | 22 | -2 | 14 | 6 |
| 30 Sep 21 | 16 | -11 | 14 | 9 |
| 30 Jun 21 | 15 | -11 | 15 | 9 |
| 31 Mar 21 | 12 | -14 | 14 | 9 |
| 31 Dec 20 | 0 | -28 | 13 | 14 |
| 30 Sep 20 | 0 | -23 | 11 | 11 |
| 30 Jun 20 | 1 | -21 | 10 | 11 |
| 31 Mar 20 | 1 | -20 | 9 | 11 |
| 31 Dec 19 | 1 | -18 | 8 | 12 |
| 30 Sep 19 | 1 | -42 | 6 | 12 |
| 30 Jun 19 | 1 | -40 | 6 | 11 |
| 31 Mar 19 | 1 | -41 | 5 | 11 |
| 31 Dec 18 | 0 | -37 | 5 | 6 |
| 30 Sep 18 | 0 | -18 | 6 | 7 |
Quality Earnings: ETON has a high level of non-cash earnings.
Growing Profit Margin: ETON became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ETON has become profitable over the past 5 years, growing earnings by 35.9% per year.
Accelerating Growth: ETON has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ETON has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1%).
Return on Equity
High ROE: ETON's Return on Equity (27.2%) is considered high.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/20 23:47 |
| End of Day Share Price | 2026/08/20 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eton Pharmaceuticals, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Gary Nachman | Canaccord Genuity |